Decrease in Shiga toxin expression using a minimal inhibitory concentration of rifampicin followed by bactericidal gentamicin treatment enhances survival of Escherichia coli O157:H7-infected BALB/c mice

Annals of Clinical Microbiology and Antimicrobials

Volumn 10, Issue , 2011, Pages

  Rahal, Elias A ^a   Kazzi, Natalie ^a   Sabra, Ahmad ^a   Abdelnoor, Alexander M ^a   Matar, Ghassan M ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Escherichia coli O157:H7; Gentamicin; Rifampicin; Shiga toxins

Indexed keywords

GENTAMICIN; RIFAMPICIN; SHIGA TOXIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL SURVIVAL; CONTROLLED STUDY; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157; GENE EXPRESSION; IN VITRO STUDY; LATEX AGGLUTINATION TEST; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MORTALITY; SURVIVAL;

ANIMALS; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; GENTAMICINS; LATEX FIXATION TESTS; MALE; MICE; MICE, INBRED BALB C; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIFAMPIN; SHIGA TOXIN; SURVIVAL ANALYSIS;

EID: 80052571538     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-10-34     Document Type: Article

References (31)

1. Levine MM. Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis 1987, 155:377-389. 10.1093/infdis/155.3.377, 3543152.
2. Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995, 333:364-368. 10.1056/NEJM199508103330608, 7609755.
3. George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (Experience of The Oklahoma TTP-HUS Registry, 1989-2007). Kidney Int Suppl 2009, S8-S10.
4. Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C, Griffin PM, Tauxe RV. Food-related illness and death in the United States. Emerg Infect Dis 1999, 5:607-625. 10.3201/eid0505.990502, 2627714, 10511517.
5. Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. Emerg Infect Dis 2005, 11:603-609.
6. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet 1998, 352:1207-1212. 10.1016/S0140-6736(98)01267-7, 9777854.
7. Jackson MP. Structure-function analyses of Shiga toxin and the Shiga-like toxins. Microb Pathog 1990, 8:235-242. 10.1016/0882-4010(90)90050-Z, 2200941.
8. Calderwood SB, Auclair F, Donohue-Rolfe A, Keusch GT, Mekalanos JJ. Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli. Proc Natl Acad Sci USA 1987, 84:4364-4368. 10.1073/pnas.84.13.4364, 305089, 3299365.
9. Hofmann SL. Southwestern Internal Medicine Conference: Shiga-like toxins in hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura. Am J Med Sci 1993, 306:398-406. 10.1097/00000441-199312000-00009, 8266983.
10. Vallance BA, Finlay BB. Exploitation of host cells by enteropathogenic Escherichia coli. Proc Natl Acad Sci USA 2000, 97:8799-8806. 10.1073/pnas.97.16.8799, 34015, 10922038.
11. Robinson CM, Sinclair JF, Smith MJ, O'Brien AD. Shiga toxin of enterohemorrhagic Escherichia coli type O157:H7 promotes intestinal colonization. Proc Natl Acad Sci USA 2006, 103:9667-9672. 10.1073/pnas.0602359103, 1475797, 16766659.
12. Carter AO, Borczyk AA, Carlson JA, Harvey B, Hockin JC, Karmali MA, Krishnan C, Korn DA, Lior H. A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home. N Engl J Med 1987, 317:1496-1500. 10.1056/NEJM198712103172403, 3317047.
13. Ostroff SM, Kobayashi JM, Lewis JH. Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA 1989, 262:355-359. 10.1001/jama.262.3.355, 2661870.
14. Pavia AT, Nichols CR, Green DP, Tauxe RV, Mottice S, Greene KD, Wells JG, Siegler RL, Brewer ED, Hannon D, et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr 1990, 116:544-551. 10.1016/S0022-3476(05)81600-2, 2181098.
15. Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection 1992, 20:25-29. 10.1007/BF01704889, 1563808.
16. Shimizu T, Ohta Y, Noda M. Shiga toxin 2 is specifically released from bacterial cells by two different mechanisms. Infect Immun 2009, 77:2813-2823. 10.1128/IAI.00060-09, 2708558, 19380474.
17. Matar GM, Rahal E. Inhibition of the transcription of the Escherichia coli O157:H7 genes coding for shiga-like toxins and intimin, and its potential use in the treatment of human infection with the bacterium. Ann Trop Med Parasitol 2003, 97:281-287. 10.1179/000349803235002146, 12803859.
18. Kanbar A, Rahal E, Matar GM. In Vitro Inhibition of the Expression of Escherichia coli O157:H7 Genes Encoding the Shiga-like Toxins by Antimicrobial Agents: Potential Use in the Treatment of Human Infection. J Appl Res 2003, 3:137-143.
19. Rahal EA, Kazzi N, Kanbar A, Abdelnoor AM, Matar GM. Role of rifampicin in limiting Escherichia coli O157:H7 Shiga-like toxin expression and enhancement of survival of infected BALB/c mice. Int J Antimicrob Agents 2011, 37:135-139. 10.1016/j.ijantimicag.2010.10.009, 21129928.
20. Ezekiel DH, Hutchins JE. Mutations affecting RNA polymerase associated with rifampicin resistance in Escherichia coli. Nature 1968, 220:276-277. 10.1038/220276a0, 4879326.
21. Jinneman KC, Yoshitomi KJ, Weagant SD. Multiplex real-time PCR method to identify Shiga toxin genes stx1 and stx2 and Escherichia coli O157:H7/H- serotype. Appl Environ Microbiol 2003, 69:6327-6333. 10.1128/AEM.69.10.6327-6333.2003, 201207, 14532101.
22. Ma Y, Mao X, Li J, Li H, Feng Y, Chen H, Luo P, Gu J, Yu S, Zeng H, et al. Engineering an anti-Stx2 antibody to control severe infections of EHEC O157:H7. Immunol Lett 2008, 121:110-115. 10.1016/j.imlet.2008.09.008, 19007817.
23. Nishikawa K, Matsuoka K, Kita E, Okabe N, Mizuguchi M, Hino K, Miyazawa S, Yamasaki C, Aoki J, Takashima S, et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc Natl Acad Sci USA 2002, 99:7669-7674. 10.1073/pnas.112058999, 124317, 12032341.
24. Rajkovic A, Smigic N, Devlieghere F. Contemporary strategies in combating microbial contamination in food chain. Int J Food Microbiol 2009,
25. Lee KM, Kim WS, Lim J, Nam S, Youn M, Nam SW, Kim Y, Kim SH, Park W, Park S. Antipathogenic properties of green tea polyphenol epigallocatechin gallate at concentrations below the MIC against enterohemorrhagic Escherichia coli O157:H7. J Food Prot 2009, 72:325-331.
26. Lacombe A, Wu VC, Tyler S, Edwards K. Antimicrobial action of the American cranberry constituents; phenolics, anthocyanins, and organic acids, against Escherichia coli O157:H7. Int J Food Microbiol 2010, 139:102-107. 10.1016/j.ijfoodmicro.2010.01.035, 20153540.
27. Ogawa M, Shimizu K, Nomoto K, Takahashi M, Watanuki M, Tanaka R, Tanaka T, Hamabata T, Yamasaki S, Takeda Y. Protective effect of Lactobacillus casei strain Shirota on Shiga toxin-producing Escherichia coli O157:H7 infection in infant rabbits. Infect Immun 2001, 69:1101-1108. 10.1128/IAI.69.2.1101-1108.2001, 97991, 11160007.
28. Oussalah M, Caillet S, Lacroix M. Mechanism of action of Spanish oregano, Chinese cinnamon, and savory essential oils against cell membranes and walls of Escherichia coli O157:H7 and Listeria monocytogenes. J Food Prot 2006, 69:1046-1055.
29. Melton-Celsa AR, O'Brien A. Structure, biology, and relative toxicity of Shiga toxin family members for cells and animals. Escherichia coli O157:H7 and other Shiga toxin-producing E coli strains 1998, 121-128. Washington, DC: American Society for Microbiology, Kaper JB, O'Brien AD.
30. Barsoumian H, El-Rami F, Abdelnoor AM. The effect of five antibacterial agents on the physiological levels of serum nitric oxide in mice. Immunopharmacol Immunotoxicol 2011,
31. Reese RE, Betts RF. Rifampin. Handbook of antibiotics 1993, 359-369. Little, Brown and Company, Boston, MA, Richard E Reese, Robert F Betts.